Vildagliptin delivers effective, safe, and well-tolerated glycemic control in diabetes management, showing strong outcomes across varied patient profiles, including those with renal impairment and risk of hypoglycemia. This case review covers two patient scenarios in detail, demonstrating the clinical value of Vildagliptin. The first case illustrates a scenario of a 64-year-old patient with Type 2 Diabetes Mellitus (T2DM) and mild chronic kidney disease achieving significant HbA1c reduction after switching from Glimepiride to Vildagliptin with Metformin, with no further hypoglycemia and stable renal function. The second case details on a 48-year-old treatment-naïve patient reaching early and sustained glycemic control using the same regimen, with improved energy, adherence, and no side effects.
The discussions are further supported by the VIOLET study, which confirms Vildagliptin’s efficacy in lowering fasting and postprandial blood glucose, its excellent safety and adherence profile, and additional metabolic benefits that extend beyond glycemic control. Click to read for more details.